Trovagene Announces Agreement with FedMed

Trovagene, Inc. TROV announced today that it has entered into an agreement with FedMed, Inc. (FedMed) establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring℠ (PCM) tests and services. Under the agreement, Trovagene's PCM services are covered as a participating laboratory testing provider for clients of FedMed, which include major health insurers such as Aetna, Cigna and Humana, and encompasses over 550,000 in-network physicians nationwide. "A major focus of FedMed is to provide innovative solutions for the healthcare community, particularly in areas such as cancer, where there is a high need to improve patient care and deliver that care in an efficient manner," said Brian Moffitt, chief operating officer of FedMed. "In line with our core strategy, we are extremely pleased to offer Trovagene's non-invasive, clinically actionable tests and services to oncologists and their patients within our national provider network." "FedMed is among the largest national provider networks in the country, and this agreement is an important step in our ability to offer oncologists and their patients access to our liquid biopsy testing See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsContractsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!